Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 56Sarcoma 32Gynecologic 14Thoracic 10Breast 10Head & Neck 9Gastrointestinal 9Other solid neoplasm 8Endocrine 6Dermatologic 5CNS 5Tumor-Agnostic 4NET 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neuroendocrine Tumors 2

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × pazopanib × NET × Clear all
NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
44 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT01099540 2015-12-29

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Samsung Medical Center

Phase 2 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡